DENTSPLY SIRONA Inc. XRAY

StockStory ranks XRAY among value stocks to avoid: constant-currency revenue growth declined over the last two years; five-year EPS fell 13.6% annually; returns on capital turned negative, signaling value destruction as legacy profit centers age. At about $10.06, forward P/E is 6.4x. Yum China (YUMC) is another value trap with large revenue base and 5.5% revenue growth over seven years, weak same-store sales, 20.3% gross margin, trading around $41.58 (12.9x forward P/E). One value stock to buy is Matador Resources (MTDR): revenue growth 29.5% over ten years, gross margin 82.3%, free cash flow margin 24.8%, stock around $52.26, forward P/E 6.4x. The piece also promotes momentum stock signals and offers free research reports. Weak growth, declining profitability, and negative returns on capital for XRAY could moderately weigh on sentiment and near-term performance.

DENTSPLY SIRONA Inc. (XRAY) posted Q2 earnings exceeding forecasts while issuing unchanged guidance and facing margin pressures. Q2 earnings beat signals short-term strength yet steady guidance and margin issues suggest limited long-term shifts.

DENTSPLY SIRONA Inc. returned to profit, prompting investors to assess its valuation. Profit recovery signals improved financials that may moderately shift market sentiment and stock performance.

DENTSPLY SIRONA Inc. reports profit recovery and reaffirms its 2026 outlook, prompting questions on whether these developments shift the investment thesis for XRAY. Profit recovery combined with reaffirmed long-term outlook signals financial stabilization likely to produce moderate effects on XRAY trajectory and sentiment.

Dentsply Sirona (XRAY) returned to profit while sales continued to decline. Profit recovery signals operational improvements yet persistent sales decline may pressure near-term valuation and outlook.

Dentsply Sirona's Q2 earnings call drew analyst questions on operational performance, product strategy, and growth outlook. Earnings call analyst questions can moderately shape investor views on financial results and strategy.

Dentsply Sirona (XRAY) released its Q2 2026 earnings call transcript covering quarterly financial results, executive commentary, and forward outlook. Quarterly earnings data and guidance can shift near-term investor sentiment and valuation.

DENTSPLY SIRONA Inc. Q2 turnaround progress slowed by market and segment headwinds. Market and segment headwinds slowed DENTSPLY SIRONA Q2 turnaround progress with moderate effect on performance trajectory.

DENTSPLY SIRONA Inc. conducted its Q2 earnings call, outlining financial results, operational updates, and forward-looking guidance for the dental products company. Q2 earnings details and guidance offer moderate insight into financial performance and strategy that can sway near-term investor views.

DENTSPLY SIRONA (XRAY) shares appear 1% undervalued ahead of earnings that will test the company's recovery narrative. Earnings results can moderately shift investor views on recovery progress and near-term valuation.

DENTSPLY SIRONA Inc. Q2 2026 earnings call covered financial results, revenue, margins, and forward outlook. Quarterly earnings figures can moderately shift near-term investor views and valuation.

Dentsply Sirona Inc. reported its second quarter 2026 financial results. Quarterly earnings releases deliver core financial metrics that typically drive immediate stock price movements and valuation shifts.

DENTSPLY SIRONA Inc. (XRAY) exceeded Q2 earnings and revenue estimates. Beating Q2 earnings and revenue estimates produces a positive but limited short-term lift to stock price and sentiment without altering long-term company trajectory.

Dentsply Sirona beat Q2 CY2026 sales expectations. Quarterly sales beat signals moderate positive revenue momentum with limited long-term trajectory shift.

DENTSPLY SIRONA Inc. (XRAY) prepares to report Q2 earnings with focus on resulting stock implications. Earnings release carries moderate potential to shift near-term stock price and sentiment.

Dentsply Sirona (XRAY) faces ongoing business challenges and explores options to reverse declining performance in the dental equipment sector. Discussion of turnaround potential signals moderate effects on financial outlook and investor views without immediate major shifts.

Dentsply Sirona expands Medline Sinclair relationship to advance commercial growth strategy in Canada. Expanded Canadian partnership supports regional sales growth and positioning but remains limited in global scope.

PDS Health surpassed five million CEREC chairside restorations using Dentsply Sirona technology, marking a milestone in scaled digital dentistry adoption. Milestone with CEREC technology signals increased adoption that may support future sales growth and market positioning for Dentsply Sirona.

DENTSPLY SIRONA appoints a new veteran CFO expected to drive capital allocation decisions and shape overall corporate strategy for XRAY. New CFO appointment at DENTSPLY SIRONA introduces potential shifts in capital allocation and corporate strategy.

Dentsply Sirona (XRAY) shares fell 13.5% since the last earnings report, with analysis focused on whether the stock can rebound from the decline. Post-earnings price drop reflects negative market reaction that can moderately sway short-term sentiment and valuation.

Dentsply Sirona expands Nashville dental partnership with potential effects on XRAY investors and company performance. Nashville partnership expansion signals moderate strategic growth likely to influence operations without major trajectory shift.

Dentsply Sirona intensifies focus on digital dentistry by integrating AI technologies and expanding global reach to drive growth and innovation. AI integration and market expansion in digital dentistry signal major strategic advancements boosting long-term competitiveness and investor confidence.

DENTSPLY SIRONA Inc. (XRAY) stock dropped after Q1 earnings missed estimates and margins contracted. Q1 earnings miss and margin contraction directly impair financial results and investor confidence, likely hindering near-term performance.

Dentsply Sirona (XRAY) released Q1 2026 earnings call transcript detailing quarterly financial results, management commentary, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook with potential to significantly sway investor sentiment and stock trajectory.

DENTSPLY SIRONA Inc. (XRAY) released highlights from its Q1 earnings call, detailing financial results, operational updates, and future outlook. Q1 earnings call highlights cover financial performance, guidance, and strategic initiatives poised to significantly shape future market performance and investor sentiment.

DENTSPLY SIRONA Inc. released Q1 2026 earnings call summary detailing quarterly financial performance, guidance, and strategic updates. Q1 2026 earnings call summary delivers key financial metrics, outlook, and strategies poised to significantly sway investor confidence and market performance.

DENTSPLY SIRONA Inc. (XRAY) reported Q1 earnings, analyzing key metrics for performance insights. Q1 earnings reports reveal financial results and guidance that significantly influence stock price and future trajectory.

Dentsply Sirona (NASDAQ:XRAY) beat Q1 CY2026 sales expectations. Beating quarterly sales expectations drives positive investor sentiment and signals strong financial health, significantly impacting stock performance.

Dentsply Sirona Inc. (XRAY) reported first quarter 2026 results, detailing financial performance metrics for the period. Quarterly earnings reports significantly impact stock performance by revealing core financial health and guidance.

Dentsply International (XRAY) reported Q1 earnings below analyst estimates. Lagging Q1 earnings highlights weaker financial performance, moderately impacting investor sentiment and near-term stock trajectory.